Therapy Detail

Therapy Name ABT-700
Therapy Description

ABT-700 (h224G11) is a monoclonal antibody that targets and inhibits c-MET (PMID: 23134362).


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ABT-700 h224G11 MET Antibody 12 ABT-700 (h224G11) is a monoclonal antibody that targets and inhibits c-MET (PMID: 23134362).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET amp Advanced Solid Tumor sensitive ABT-700 Phase I Actionable In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01472016 Phase I Docetaxel ABT-700 Cetuximab Erlotinib FOLFIRI Study of ABT-700 in Subjects With Advanced Solid Tumors Completed